0001193125-20-281037.txt : 20201029 0001193125-20-281037.hdr.sgml : 20201029 20201029160543 ACCESSION NUMBER: 0001193125-20-281037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201029 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201029 DATE AS OF CHANGE: 20201029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RESMED INC CENTRAL INDEX KEY: 0000943819 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980152841 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15317 FILM NUMBER: 201272640 BUSINESS ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: 8587462400 MAIL ADDRESS: STREET 1: 9001 SPECTRUM CENTER BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92123 8-K 1 d53808d8k.htm 8-K 8-K
RESMED INC US false 0000943819 0000943819 2020-10-29 2020-10-29

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 29, 2020

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-15317   98-0152841

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

9001 Spectrum Center Blvd.
San Diego, California 92123
(Address of Principal Executive Offices)

(858) 836-5000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.004 par value   RMD   NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  ☐

 

 

 

Item 2.02.

Disclosure of Results of Operations and Financial Condition.

On October 29, 2020 we issued the press release attached as Exhibit 99.1. It is incorporated into this report by reference. The press release describes the results of our operations for the quarter ended September 30, 2020.

 

Item 8.01.

Other Events.

On October 29, 2020 we announced that our board of directors declared a quarterly cash dividend of US $0.39 per share. The dividend will have a record date of November 12, 2020, payable on December 17, 2020. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 11, 2020 for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 11, 2020 through November 12, 2020, inclusive.

 

Item 9.01.

Financial Statements and Exhibits.

(d)    Exhibits

 

Exhibits:

   

Description of Document

99.1    Press Release dated October 29, 2020 regarding results of operations
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

Date: October 29, 2020     RESMED INC.
    (registrant)
    By:  

/s/ Brett Sandercock

    Name:   Brett Sandercock
    Its:   Chief Financial Officer

 

-3-

EX-99.1 2 d53808dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO  

 

For investors    For media
Amy Wakeham    Jayme Rubenstein
+1 858-836-5000    +1 858-836-6798
investorrelations@resmed.com    news@resmed.com

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2021

 

  •  

Year-over-year revenue grows 10%, non-GAAP operating profit up 24%

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, October 29, 2020 – ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended September 30, 2020.

First Quarter 2021 Highlights

All comparisons are to the prior year period

 

  •  

Revenue increased 10% to $751.9 million; up 9% on a constant currency basis

 

  •  

GAAP gross margin of 58.3%; non-GAAP gross margin expanded 30 bps to 59.9%

 

  •  

Net operating profit increased 27%; non-GAAP operating profit up 24%

 

  •  

GAAP diluted earnings per share of $1.22; non-GAAP diluted earnings per share of $1.27

“Our first quarter results reflect solid performance and positive trends across our business,” said Mick Farrell, ResMed’s CEO. “During the quarter, we continued to support the global COVID-19 pandemic response, providing ventilators, masks, and circuits to countries in need around the world. In our core markets of sleep apnea, COPD, and asthma, we are encouraged by the sequential improvement in new patient volume, as well as the ongoing strong adoption of our mask and accessories resupply programs. We have accelerated the launch of digital health solutions to help clinicians remotely diagnose, treat, and manage patients during the pandemic and beyond. Our global team is effectively managing SG&A expenses, while investing in broad-based R&D programs to help accelerate our ResMed 2025 growth strategy: improving 250 million lives in out-of-hospital healthcare in 2025.”

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  2  of 10

 

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

 

     Three Months Ended  
     September 30,
2020		     September 30,
2019		     % Change     Constant
Currency (A)		  

Revenue

    $ 751.9     $ 681.1       10 %      9 % 

Gross margin (B)

      58.3 %      57.5 %      1    

Non-GAAP gross margin (B)

      59.9 %      59.6 %      1    

Selling, general and administrative expenses

      159.0       167.4       (5 )      (7 ) 

Research and development expenses

      54.5       48.0       14       12  

Income from operations

      216.9       171.1       27    

Non-GAAP income from operations (B)

      237.1       191.0       24    

Net income

      178.4       120.1       48    

Non-GAAP net income (B)

      185.4       135.4       37    

Diluted earnings per share

    $ 1.22     $ 0.83       47    

Non-GAAP diluted earnings per share (B)

    $ 1.27     $ 0.93       37    

 

(A)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of First Quarter Results

All comparisons are to the prior year period unless otherwise noted

 

  •  

Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 9 percent, driven by strong sales across our mask product portfolio and increased demand for our ventilators due to COVID-19, partially offset by a decrease in demand for our sleep devices.

 

  •  

Revenue in combined Europe, Asia, and other markets grew by 10 percent on a constant currency basis, primarily driven by sales across our device and mask product portfolio, including increased demand for our ventilators due to COVID-19.

 

  •  

Software as a Service revenue increased by 6 percent, due to continued growth in resupply service offerings and stabilizing patient flow in out-of-hospital care settings.

 

  •  

Gross margin expanded by 80 basis points while non-GAAP gross margin expanded by 30 basis points. These expansions were primarily due to benefits from product mix changes and foreign exchange rates, partially offset by declines in manufacturing and procurement efficiencies driven by higher air freight costs.

 

  •  

Selling, general, and administrative expenses decreased by 7 percent on a constant currency basis. SG&A expenses improved to 21.1 percent of revenue in the quarter, compared with 24.6 percent in the same period of the prior year. These changes in SG&A expenses were mainly due to savings in travel and other cost management as a result of the COVID-19 pandemic.

 

  •  

Income from operations increased by 27 percent and non-GAAP income from operations increased by 24 percent.

 

  •  

Net income grew by 48 percent and diluted earnings per share grew by 47 percent, largely attributable to the impact of legal settlement expenses in the prior year. Non-GAAP net income grew by 37 percent and non-GAAP diluted earnings per share grew by 37 percent, predominantly attributable to strong ventilator device sales and controlled operating costs.

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  3  of 10

 

  •  

Cash flow from operations for the quarter was $144.0 million, compared to net income in the current quarter of $178.4 million. During the quarter we paid $56.5 million in dividends.

Other Business and Operational Highlights

 

  •  

Introduced the AirTouch N20 foam CPAP mask with a memory foam cushion, the softest nasal mask ever. AirTouch N20 uses the same patented UltraSoft memory foam cushion as the full face AirTouch F20, adapting to the curves and contours of each face to create a soft, personalized fit designed to increase comfort and CPAP adherence.

 

  •  

Two ResMed masks, the AirFit N30 and AirFit F30i, received Good Design Australia Awards in the Product Design category for achieving the highest level of design and innovation in service to sleep apnea patients worldwide. ResMed has now won eight Good Design Australia Awards.

 

  •  

ResMed CEO Mick Farrell was named Large Public Company CEO of the Year by the San Diego Business Journal. Farrell was honored for leading ResMed’s response to the global pandemic and the company’s swift pivot to increasing its manufacturing of lifesaving ventilators and bilevel devices by more than 3.5 times during the first six months of the COVID-19 crisis. ResMed also accelerated the launch of new digital health solutions to help clinicians remotely diagnose, treat, and manage sleep apnea, COPD, and asthma patients during the pandemic and beyond.

Dividend program

The ResMed board of directors today declared a quarterly cash dividend of $0.39 per share. The dividend will have a record date of November 12, 2020, payable on December 17, 2020. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 11, 2020, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from November 11, 2020, through November 12, 2020, inclusive.     

Webcast details

ResMed will discuss its first quarter fiscal year 2021 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q1 2021 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 800-585-8367 (U.S.) or +1 416-621-4642 (outside U.S.) and entering the passcode 2192036. The telephone replay will be available until November 12, 2020.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  4  of 10

 

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

– More –

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  5  of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Income

(Unaudited; $ in thousands, except for per share amounts)

 

     Three Months Ended  
     September 30,
2020		     September 30,
2019		  

Net revenue

    $ 751,944     $ 681,056  

Cost of sales

      301,304       276,001  

Amortization of acquired intangibles (1)

      11,979       13,436  
  

 

 

    

 

 

  

Total cost of sales

    $ 313,283     $ 289,437  
  

 

 

    

 

 

  

Gross profit

    $ 438,661     $ 391,619  

Selling, general and administrative

      158,989       167,440  

Research and development

      54,533       48,033  

Amortization of acquired intangibles (1)

      8,243       5,044  
  

 

 

    

 

 

  

Total operating expenses

    $ 221,765     $ 220,517  

Income from operations

      216,896       171,102  

Other income (expenses), net:

     

Interest income (expense), net

    $ (6,725 )    $ (10,543 ) 

Loss attributable to equity method investments

      (2,288 )      (6,863 ) 

Other, net

      7,971       (3,109 ) 
  

 

 

    

 

 

  

Total other income (expenses), net

      (1,042 )      (20,515 ) 
  

 

 

    

 

 

  

Income before income taxes

    $ 215,854     $ 150,587  

Income taxes

      37,482       30,439  
  

 

 

    

 

 

  

Net income

    $ 178,372     $ 120,148  
  

 

 

    

 

 

  

Basic earnings per share

    $ 1.23     $ 0.84  

Diluted earnings per share

    $ 1.22     $ 0.83  

Non-GAAP diluted earnings per share (1)

    $ 1.27     $ 0.93  

Basic shares outstanding

      144,900       143,719  

Diluted shares outstanding

      146,100       145,099  

 

(1)

See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

– More –

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  6  of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

 

     September 30,
2020		     June 30,
2020		  

ASSETS

     

Current assets:

     

Cash and cash equivalents

    $ 421,414     $ 463,156  

Accounts receivable, net

      464,892       474,643  

Inventories

      478,006       416,915  

Prepayments and other current assets

      178,297       168,745  
  

 

 

    

 

 

  

Total current assets

    $ 1,542,609     $ 1,523,459  

Non-current assets:

     

Property, plant and equipment, net

    $ 424,819     $ 417,335  

Operating lease right-of-use assets

      124,473       118,348  

Goodwill and other intangibles, net

      2,332,637       2,338,492  

Deferred income taxes and other non-current assets

      196,306       189,742  
  

 

 

    

 

 

  

Total non-current assets

    $ 3,078,235     $ 3,063,917  
  

 

 

    

 

 

  

Total assets

    $ 4,620,844     $ 4,587,376  
  

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ EQUITY:

     

Current liabilities:

     

Accounts payable

    $ 117,589     $ 135,786  

Accrued expenses

      269,859       270,353  

Operating lease liabilities, current

      21,329       21,263  

Deferred revenue

      102,035       98,617  

Income taxes payable

      68,053       64,755  

Short-term debt

      11,988       11,987  
  

 

 

    

 

 

  

Total current liabilities

    $ 590,853     $ 602,761  

Non-current liabilities:

     

Deferred revenue

    $ 83,887     $ 87,307  

Deferred income taxes

      13,007       13,011  

Operating lease liabilities, non-current

      111,183       101,880  

Other long term liabilities

      8,568       8,347  

Long-term debt

      1,044,435       1,164,133  

Long-term income taxes payable

      90,051       112,910  
  

 

 

    

 

 

  

Total non-current liabilities

    $ 1,351,131     $ 1,487,588  
  

 

 

    

 

 

  

Total liabilities

    $ 1,941,984     $ 2,090,349  
  

 

 

    

 

 

  

STOCKHOLDERS’ EQUITY:

     

Common stock

    $ 580     $ 580  

Additional paid-in capital

      1,588,018       1,570,694  

Retained earnings

      2,953,709       2,832,991  

Treasury stock

      (1,623,256 )      (1,623,256 ) 

Accumulated other comprehensive income

      (240,191 )      (283,982 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

    $ 2,678,860     $ 2,497,027  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 4,620,844     $ 4,587,376  
  

 

 

    

 

 

  

– More –

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  7  of 10

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands)

 

     Three Months Ended  
     September 30,
2020		     September 30,
2019		  

Cash flows from operating activities:

     

Net income

    $ 178,372     $ 120,148  

Adjustment to reconcile net income to cash provided by operating activities:

     

Depreciation and amortization

      39,466       37,954  

Amortization of right-of-use-assets

      10,422       5,963  

Stock-based compensation costs

      16,071       13,256  

Loss attributable to equity method investments

      2,288       6,863  

(Gain) loss on equity investment

      (8,476 )      2,590  

Changes in fair value of business combination contingent consideration

      —         (8 ) 

Changes in operating assets and liabilities:

     

Accounts receivable, net

      16,110       28,286  

Inventories, net

      (52,396 )      (14,204 ) 

Prepaid expenses, net deferred income taxes and other current assets

      3,415       (8,407 ) 

Accounts payable, accrued expenses and other

      (61,273 )      (30,078 ) 
  

 

 

    

 

 

  

Net cash provided by operating activities

    $ 143,999     $ 162,363  

Cash flows from investing activities:

     

Purchases of property, plant and equipment

      (13,501 )      (22,671 ) 

Patent registration costs

      (5,237 )      (2,069 ) 

Business acquisitions, net of cash acquired

      —         —    

Purchases of investments

      (8,196 )      (2,741 ) 

Proceeds / (Payments) on maturity of foreign currency contracts

      4,824       (5,743 ) 
  

 

 

    

 

 

  

Net cash used in investing activities

    $ (22,110 )    $ (33,224 ) 

Cash flows from financing activities:

     

Proceeds from issuance of common stock, net

      1,026       5,609  

Taxes paid related to net share settlement of equity awards

      227       (326 ) 

Payment of business combination contingent consideration

      —         (302 ) 

Proceeds from borrowings, net of borrowing costs

      55,000       565,000  

Repayment of borrowings

      (175,000 )      (614,003 ) 

Dividends paid

      (56,511 )      (56,052 ) 
  

 

 

    

 

 

  

Net cash used in financing activities

    $ (175,258 )    $ (100,074 ) 
  

 

 

    

 

 

  

Effect of exchange rate changes on cash

    $ 11,627     $ (4,039 ) 
  

 

 

    

 

 

  

Net increase / (decrease) in cash and cash equivalents

      (41,742 )      25,026  

Cash and cash equivalents at beginning of period

      463,156       147,128  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 421,414     $ 172,154  
  

 

 

    

 

 

  

– More –

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  8  of 10

 

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” excludes amortization expense from acquired intangibles related to cost of sales and are reconciled below:

 

     Three Months Ended  
     September 30,
2020		     September 30,
2019		  

Revenue

    $ 751,944   $ 681,056

Add back: Deferred revenue fair value adjustment (A)

      —         1,445
  

 

 

    

 

 

  

Non-GAAP Revenue

    $ 751,944   $ 682,501

GAAP Cost of sales

    $ 313,283   $ 289,437

Less: Amortization of acquired intangibles (A)

      (11,979 )      (13,436 ) 
  

 

 

    

 

 

  

Non-GAAP cost of sales

    $ 301,304   $ 276,001

GAAP gross profit

      438,661     391,619

GAAP gross margin

      58.3 %      57.5 % 

Non-GAAP gross profit

      450,640     406,500

Non-GAAP gross margin

      59.9 %      59.6 % 

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

 

     Three Months Ended  
     September 30,
2020		      September 30,
2019		  

GAAP income from operations

    $ 216,896    $ 171,102

Amortization of acquired intangibles - cost of sales (A)

      11,979      13,436

Amortization of acquired intangibles - operating expenses (A)

      8,243      5,044

Deferred revenue fair value adjustment (A)

      —          1,445
  

 

 

     

 

 

  

Non-GAAP income from operations

    $ 237,118    $ 191,027
  

 

 

     

 

 

  

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  9  of 10

 

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

     Three Months Ended  
     September 30,
2020		      September 30,
2019		  

GAAP net income

    $ 178,372    $ 120,148

Amortization of acquired intangibles - cost of sales, net of tax (A)

      9,169      10,267

Amortization of acquired intangibles - operating expenses, net of tax (A)

      6,309      3,855

Deferred revenue fair value adjustment, net of tax (A)

      —          1,107

(Gain) loss on equity investments (A)

      (8,476 )       —    
  

 

 

     

 

 

  

Non-GAAP net income (A)

    $ 185,374    $ 135,377
  

 

 

     

 

 

  

Diluted shares outstanding

      146,100      145,099

GAAP diluted earnings per share

    $ 1.22    $ 0.83

Non-GAAP diluted earnings per share (A)

    $ 1.27    $ 0.93

 

(A)

ResMed adjusts for the impact of the amortization of acquired intangibles, deferred revenue fair value adjustment and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

– More –

RMD First Quarter 2021 Earnings Press Release – October 29, 2020   Page  10  of 10

 

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in millions, except for per share amounts)

 

     Three Months Ended  
     September 30,
2020 (A)		      September 30,
2019 (A)		      % Change     Constant
Currency (B)		  

U.S., Canada and Latin America

           

Devices

    $ 197.4      $ 186.9        6 %   

Masks and other

      205.8        183.4        12    
  

 

 

     

 

 

     

 

 

    

Total Sleep and Respiratory Care

    $ 403.2      $ 370.3        9    

Software as a Service

      92.1        86.9        6    
  

 

 

     

 

 

     

 

 

    

Total

    $ 495.3      $ 457.2        8    
  

 

 

     

 

 

     

 

 

    

Combined Europe, Asia and other markets

           

Devices

    $ 176.0      $ 151.9        16 %      11 % 

Masks and other

      80.6        72.0        12       8  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total Sleep and Respiratory Care

    $ 256.6      $ 223.9        15       10  

Global revenue

           

Devices

    $ 373.4      $ 338.8        10 %      8 % 

Masks and other

      286.4        255.4        12       11  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total Sleep and Respiratory Care

    $ 659.8      $ 594.2        11       9  

Software as a Service

      92.1        86.9        6       6  
  

 

 

     

 

 

     

 

 

    

 

 

  

Total

    $ 751.9      $ 681.1        10       9  
  

 

 

     

 

 

     

 

 

    

 

 

  

 

(A)

Totals and subtotals may not add due to rounding.

(B)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

– End –

EX-101.SCH 3 rmd-20201029.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rmd-20201029_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Address, Country Entity Address, Country Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rmd-20201029_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g53808g1029083138420.jpg GRAPHIC begin 644 g53808g1029083138420.jpg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end XML 7 d53808d8k_htm.xml IDEA: XBRL DOCUMENT 0000943819 2020-10-29 2020-10-29 RESMED INC US false 0000943819 8-K 2020-10-29 DE 001-15317 98-0152841 9001 Spectrum Center Blvd. San Diego CA 92123 (858) 836-5000 false false false false Common Stock, $0.004 par value RMD NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Oct. 29, 2020
Cover [Abstract]  
Entity Registrant Name RESMED INC
Entity Address, Country US
Amendment Flag false
Entity Central Index Key 0000943819
Document Type 8-K
Document Period End Date Oct. 29, 2020
Entity Incorporation State Country Code DE
Entity File Number 001-15317
Entity Tax Identification Number 98-0152841
Entity Address, Address Line One 9001 Spectrum Center Blvd.
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92123
City Area Code (858)
Local Phone Number 836-5000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.004 par value
Trading Symbol RMD
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d53808d8k.htm d53808dex991.htm rmd-20201029.xsd rmd-20201029_lab.xml rmd-20201029_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d53808d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d53808d8k.htm" ] }, "labelLink": { "local": [ "rmd-20201029_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rmd-20201029_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rmd-20201029.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rmd", "nsuri": "http://investor.resmed.com/20201029", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d53808d8k.htm", "contextRef": "duration_2020-10-29_to_2020-10-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d53808d8k.htm", "contextRef": "duration_2020-10-29_to_2020-10-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://investor.resmed.com//20201029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-20-281037-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-281037-xbrl.zip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